Cargando…

External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer

BACKGROUND: This study was conducted to validate a pretreatment (i.e. prior to neoadjuvant chemoradiotherapy) pathological staging system in the resection specimen after neoadjuvant chemoradiotherapy for esophageal cancer. The study investigated the prognostic value of pretreatment pathological T an...

Descripción completa

Detalles Bibliográficos
Autores principales: Brinkmann, Sebastian, Noordman, Bo J., Hölscher, Arnulf H., Biermann, Katharina, van Klaveren, David, Bollschweiler, Elfriede, Pütz, Katharina, van Lanschot, J. Jan B., Drebber, Uta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060166/
https://www.ncbi.nlm.nih.gov/pubmed/31691114
http://dx.doi.org/10.1245/s10434-019-08024-0
_version_ 1783504173544767488
author Brinkmann, Sebastian
Noordman, Bo J.
Hölscher, Arnulf H.
Biermann, Katharina
van Klaveren, David
Bollschweiler, Elfriede
Pütz, Katharina
van Lanschot, J. Jan B.
Drebber, Uta
author_facet Brinkmann, Sebastian
Noordman, Bo J.
Hölscher, Arnulf H.
Biermann, Katharina
van Klaveren, David
Bollschweiler, Elfriede
Pütz, Katharina
van Lanschot, J. Jan B.
Drebber, Uta
author_sort Brinkmann, Sebastian
collection PubMed
description BACKGROUND: This study was conducted to validate a pretreatment (i.e. prior to neoadjuvant chemoradiotherapy) pathological staging system in the resection specimen after neoadjuvant chemoradiotherapy for esophageal cancer. The study investigated the prognostic value of pretreatment pathological T and N categories (prepT and prepN categories) in both an independent and a combined patient cohort. METHODS: Patients with esophageal cancer treated with neoadjuvant chemotherapy and esophagectomy between 2012 and 2015 were included. PrepT and prepN categories were estimated based on the extent of tumor regression and regressional changes of lymph nodes in the resection specimen. The difference in Akaike’s information criterion (ΔAIC) was used to assess prognostic performance. PrepN and ypN categories were combined to determine the effect of nodal sterilization on prognosis. A multivariable Cox regression model was used to identify combined prepN and ypN categories as independent prognostic factors. RESULTS: The prognostic strength of the prepT category was better than the cT and ypT categories (ΔAIC 7.7 vs. 3.0 and 2.9, respectively), and the prognostic strength of the prepN category was better than the cN category and similar to the ypN category (ΔAIC 29.2 vs. − 1.0 and 27.9, respectively). PrepN + patients who became ypN0 had significantly worse survival than prepN0 patients (2-year overall survival 69% vs. 86% in 137 patients; p = 0.044). Similar results were found in a combined cohort of 317 patients (2-year overall survival 62% vs. 85%; p = 0.002). Combined prepN/ypN stage was independently associated with overall survival. CONCLUSIONS: These results independently confirm the prognostic value of prepTNM staging. PrepTNM staging is of additional prognostic value to cTNM and ypTNM. PrepN0/ypN0 patients have a better survival than prepN +/ypN0 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-019-08024-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7060166
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70601662020-03-23 External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer Brinkmann, Sebastian Noordman, Bo J. Hölscher, Arnulf H. Biermann, Katharina van Klaveren, David Bollschweiler, Elfriede Pütz, Katharina van Lanschot, J. Jan B. Drebber, Uta Ann Surg Oncol Thoracic Oncology BACKGROUND: This study was conducted to validate a pretreatment (i.e. prior to neoadjuvant chemoradiotherapy) pathological staging system in the resection specimen after neoadjuvant chemoradiotherapy for esophageal cancer. The study investigated the prognostic value of pretreatment pathological T and N categories (prepT and prepN categories) in both an independent and a combined patient cohort. METHODS: Patients with esophageal cancer treated with neoadjuvant chemotherapy and esophagectomy between 2012 and 2015 were included. PrepT and prepN categories were estimated based on the extent of tumor regression and regressional changes of lymph nodes in the resection specimen. The difference in Akaike’s information criterion (ΔAIC) was used to assess prognostic performance. PrepN and ypN categories were combined to determine the effect of nodal sterilization on prognosis. A multivariable Cox regression model was used to identify combined prepN and ypN categories as independent prognostic factors. RESULTS: The prognostic strength of the prepT category was better than the cT and ypT categories (ΔAIC 7.7 vs. 3.0 and 2.9, respectively), and the prognostic strength of the prepN category was better than the cN category and similar to the ypN category (ΔAIC 29.2 vs. − 1.0 and 27.9, respectively). PrepN + patients who became ypN0 had significantly worse survival than prepN0 patients (2-year overall survival 69% vs. 86% in 137 patients; p = 0.044). Similar results were found in a combined cohort of 317 patients (2-year overall survival 62% vs. 85%; p = 0.002). Combined prepN/ypN stage was independently associated with overall survival. CONCLUSIONS: These results independently confirm the prognostic value of prepTNM staging. PrepTNM staging is of additional prognostic value to cTNM and ypTNM. PrepN0/ypN0 patients have a better survival than prepN +/ypN0 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-019-08024-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-11-05 2020 /pmc/articles/PMC7060166/ /pubmed/31691114 http://dx.doi.org/10.1245/s10434-019-08024-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Thoracic Oncology
Brinkmann, Sebastian
Noordman, Bo J.
Hölscher, Arnulf H.
Biermann, Katharina
van Klaveren, David
Bollschweiler, Elfriede
Pütz, Katharina
van Lanschot, J. Jan B.
Drebber, Uta
External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title_full External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title_fullStr External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title_full_unstemmed External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title_short External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
title_sort external validation of pretreatment pathological tumor extent in patients with neoadjuvant chemoradiotherapy plus surgery for esophageal cancer
topic Thoracic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060166/
https://www.ncbi.nlm.nih.gov/pubmed/31691114
http://dx.doi.org/10.1245/s10434-019-08024-0
work_keys_str_mv AT brinkmannsebastian externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT noordmanboj externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT holscherarnulfh externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT biermannkatharina externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT vanklaverendavid externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT bollschweilerelfriede externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT putzkatharina externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT vanlanschotjjanb externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer
AT drebberuta externalvalidationofpretreatmentpathologicaltumorextentinpatientswithneoadjuvantchemoradiotherapyplussurgeryforesophagealcancer